Seaport Therapeutics Closes $225 Million Oversubscribed Series B Financing Round
Glyph™ is Seaport’s proprietary technology platform which uses the lymphatic system to enable and enhance the oral administration of drugs. With the Glyph platform, drugs are absorbed like dietary fats through the intestinal lymphatic system and transported into circulation. The Glyph platform has the potential to be widely applied to many therapeutic molecules that have high first-pass metabolism leading to low bioavailability and/or side effects, including liver enzyme elevations or hepatotoxicity.
https://www.businesswire.com/news/hom...
![Fork bombs [Windows + Linux]](https://images.videosashka.com/watch/r1Z5DjygsjE)
